Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P(1) Receptor Modulator in Clinical Trials

[Image: see text] Clinical validation of S1P receptor modulation therapy was achieved with the approval of fingolimod (Gilenya, 1) as the first oral therapy for relapsing remitting multiple sclerosis. However, 1 causes a dose-dependent reduction in the heart rate (bradycardia), which occurs within h...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :ACS Med Chem Lett
Главные авторы: Dhar, T. G. Murali, Xiao, Hai-Yun, Xie, Jenny, Lehman-McKeeman, Lois D., Wu, Dauh-Rurng, Dabros, Marta, Yang, Xiaoxia, Taylor, Tracy L., Zhou, Xia D., Heimrich, Elizabeth M., Thomas, Rochelle, McIntyre, Kim W., Warrack, Bethanne, Shi, Hong, Levesque, Paul C., Zhu, Jia L., Hennan, James, Balimane, Praveen, Yang, Zheng, Marino, Anthony M., Cornelius, Georgia, D’Arienzo, Celia J., Mathur, Arvind, Shen, Ding Ren, Cvijic, Mary Ellen, Salter-Cid, Luisa, Barrish, Joel C., Carter, Percy H., Dyckman, Alaric J.
Формат: Artigo
Язык:Inglês
Опубликовано: American Chemical Society 2016
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4789672/
https://ncbi.nlm.nih.gov/pubmed/26985316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.5b00448
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы